296 related articles for article (PubMed ID: 33576117)
1. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
Kanana N; Ben David MA; Nissan N; Yagil Y; Shalmon A; Halshtok O; Gotlieb M; Faermann R; Klang E; Samoocha D; Yassin M; Davidson T; Zippel D; Madorsky Feldman D; Friedman E; Kaidar-Person O; Sklair Levy M
Breast J; 2021 May; 27(5):441-447. PubMed ID: 33576117
[TBL] [Abstract][Full Text] [Related]
2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
4. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
[TBL] [Abstract][Full Text] [Related]
5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
6. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
Heemskerk-Gerritsen BA; Menke-Pluijmers MB; Jager A; Tilanus-Linthorst MM; Koppert LB; Obdeijn IM; van Deurzen CH; Collée JM; Seynaeve C; Hooning MJ
Ann Oncol; 2013 Aug; 24(8):2029-35. PubMed ID: 23576707
[TBL] [Abstract][Full Text] [Related]
7. Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
Stanek K; Zimovjanova M; Suk P; Jonas F; Zimovjanova A; Molitor M; Mestak O
Aesthetic Plast Surg; 2022 Apr; 46(2):706-711. PubMed ID: 34342702
[TBL] [Abstract][Full Text] [Related]
8. Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
Galmor L; Bernstein-Molho R; Sklair-Levy M; Madoursky-Feldman D; Zippel D; Laitman Y; Friedman E
Breast Cancer Res Treat; 2021 Jan; 185(2):391-399. PubMed ID: 33000375
[TBL] [Abstract][Full Text] [Related]
9. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Stjepanovic N; Lubinski J; Moller P; Randall Armel S; Foulkes WD; Tung N; Neuhausen SL; Kotsopoulos J; Sun P; Sun S; Eisen A; Narod SA;
Breast Cancer Res Treat; 2021 Jun; 187(2):515-523. PubMed ID: 33423179
[TBL] [Abstract][Full Text] [Related]
11. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
[TBL] [Abstract][Full Text] [Related]
12. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
Garstka M; Henriquez A; Kelly BN; Webster A; Khubchandani JA; Hughes K; Nguyen A; Oseni T; Specht M; Coopey SB; Gadd MA; Smith BL
Ann Surg Oncol; 2021 Oct; 28(10):5657-5662. PubMed ID: 34296361
[TBL] [Abstract][Full Text] [Related]
13. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
[TBL] [Abstract][Full Text] [Related]
15. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
19. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Tung N; Armel S; Senter L; Singer CF; Fruscio R; Couch F; Weitzel JN; Karlan B; Foulkes WD; Moller P; Eisen A; Ainsworth P; Neuhausen SL; Olopade O; Sun P; Gronwald J; Narod SA;
Breast Cancer Res Treat; 2019 Jun; 175(2):443-449. PubMed ID: 30756284
[TBL] [Abstract][Full Text] [Related]
20. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]